KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Shares Outstanding (2016 - 2025)

Jazz Pharmaceuticals has reported Shares Outstanding over the past 16 years, most recently at $61.4 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $61.4 million for Q4 2025, up 1.33% from a year ago — trailing twelve months through Dec 2025 was $61.4 million (up 1.33% YoY), and the annual figure for FY2025 was $61.4 million, up 1.33%.
  • Shares Outstanding for Q4 2025 was $61.4 million at Jazz Pharmaceuticals, up from $4.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding for JAZZ hit a ceiling of $63.4 million in Q2 2023 and a floor of $4.0 million in Q2 2021.
  • Median Shares Outstanding over the past 5 years was $60.6 million (2024), compared with a mean of $41.3 million.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 1472.25% in 2022 and later crashed 93.65% in 2024.
  • Jazz Pharmaceuticals' Shares Outstanding stood at $61.6 million in 2021, then increased by 2.57% to $63.2 million in 2022, then decreased by 1.52% to $62.3 million in 2023, then decreased by 2.61% to $60.6 million in 2024, then increased by 1.33% to $61.4 million in 2025.
  • The last three reported values for Shares Outstanding were $61.4 million (Q4 2025), $4.0 million (Q3 2025), and $60.6 million (Q2 2025) per Business Quant data.